查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球细菌感染治疗市场-2022-2029
市场调查报告书
商品编码
1140665

全球细菌感染治疗市场-2022-2029

Global Bacterial Infectious Diseases Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年细菌感染治疗市场价值 758 亿美元。预计在预测期内（2022-2029 年）将以 8.2% 的复合年增长率增长。

细菌感染是由引发保护性免疫反应的细菌引起的感染。它涉及体内或体外有害细菌的生长。细菌是在所有环境中发现的单细胞微生物，包括土壤、水和身体。它们以多种形状存在，包括棒状（桿菌）、球状（球菌）和螺旋状（螺旋藻）。

细菌感染可能发生在身体的许多不同部位，包括喉咙、肺、皮肤和肠道。细菌感染的特征在于各种症状，包括血尿、尿频、腹泻、不适、发烧、喉咙痛、头痛、咳嗽、疼痛、噁心、呕吐、皮疹、病变、脓肿和虚弱。细菌感染会增加危及生命的并发症的风险，例如血液中毒、肾功能衰竭和中毒性休克综合征。

市场动态

老龄化社会的到来推动市场增长

由于老年人发生细菌感染的风险很高，随着老年人口的增加，对治疗细菌感染的药物的需求也在增加。由于多种因素，老年人中观察到严重的细菌感染，包括医疗条件、免疫力减弱、不同药物的共同给药、诊断延迟以及对治疗的反应延迟或降低。

根据联合国 (UN) 的一份报告，到 2020 年，全球 65 岁及以上的人口将达到 7.27 亿。到2050年，老年人口预计将增加一倍以上，达到15亿。亚洲的老年人口数量超过欧洲和北美。尿路感染、皮肤感染、胃肠道感染、肺炎和流感在老年人中很常见。

预计抗菌素耐药性的增加将在预测期内推动治疗药物的开发。

由于耐药病原体的出现和传播，抗生素耐药性正在增加。根据世界卫生组织 (WHO) 新的全球抗菌素监测系统 (GLASS)，在 22 个国家的 50 万疑似细菌感染者中观察到抗菌素耐药性。 2020 年，30 个结核病高负担国家中约 86% 的新结核病病例。

滥用或过度使用抗生素、无法获得清洁的水和卫生设施 (WASH)、卫生设施的感染和疾病预防和控制不足、缺乏高质量和负担得起的药物、疫苗和诊断工具。有几个因素正在推动抗菌素阻力，包括缺乏准入、缺乏认识和知识，以及缺乏执法。抗菌素耐药性限制了最常见的细菌感染的治疗。在全球范围内，由现有抗菌药物无法治疗的多重耐药菌和泛耐药菌引起的传染病正在增加。由于耐药细菌的这种增加，用于治疗细菌感染的治疗剂的开髮变得活跃。细菌感染管道很强大，正在开发多种疗法。几家公司正在努力开发有效的治疗方法，以克服现有抗生素所表现出的耐药性。根据世界卫生组织（WHO）的数据，与世界卫生组织优先病原体清单相对应的大约32种抗生素正在临床开发中。在这 32 种抗生素中，只有 6 种被列为革命性抗生素。

组织和研究机构克服抗菌素耐药性的努力正在推动市场增长

一些组织和机构正在努力克服抗菌素耐药性。例如，印度政府在 NCDC 协调的“十二五”规划中启动了国家抗菌素耐药性控制计划。这种循序渐进的方法包括 35 个州立医学院实验室和 26 个州/UT。世界卫生组织 (WHO) 与被忽视疾病药物倡议 (DNDi) 签署了全球抗生素研发伙伴关係 (GARDP)。该伙伴关係旨在到 2025 年开发和提供五种新的治疗方法，针对被世卫组织确定为最大威胁的耐药细菌。

美国食品药品监督管理局 (FDA) 发起了一项“立即生成抗生素激励措施 (GAIN)”计划，以通过加快开发和批准新的抗菌剂和抗真菌剂来解决抗菌素耐药性对公众健康的威胁。）法律”被颁布。

COVID-19 影响分析

随着使用抗菌剂治疗 COVID-19 患者的细菌感染，随着 COVID-19 患者人数的增加，细菌感染药物出现了显着增长。 COVID-19 感染是由葡萄球菌、肠球菌、肺炎克雷伯菌、肠桿菌、大肠桿菌、不动桿菌和假单胞菌等多种细菌引起的。

根据 Bradley J. Langford 等人 2020 年发表在临床微生物学和传染病 (CMI) 上的一项研究，3.5% 的 COVID-19 患者和 14.3% 的 COVID-19 患者发生细菌合併感染. % 被观察到。大约 71.9% 的 COVID-19 患者接受了抗生素治疗细菌感染。主要推荐使用抗生素，如阿奇霉素、头孢曲松、槲皮素、雷帕霉素和强力霉素。阿奇霉素具有抗炎作用，可用于抑制对 COVID-19 的过度活跃的免疫反应。

流行病学

2019 年全球疾病负担、伤害和风险因素研究 (GBD) 估计，2019 年类风湿性关节炎 (RA) 的患病率为 326 万。女性受到影响的可能性是男性的两到三倍。大约有 12 名女性和 20 名男性中有 1 名在其一生中会患上炎症性自身免疫性风湿病。根据 Giegerich E 等人 2018 年的数据，2017 年克罗恩病的诊断患病率在低收入亚太地区为每 10 万人 6 人，在高收入亚太地区为每 10 万人 46 人，在欧洲为每 10 万人 46 人。在北美，每 10 万人中有 133 例，每 10 万人中有 210 例。克罗恩病的确诊患病率在 40-54 岁的人群中最高。强直性脊柱炎患病率欧洲为23.8/万，亚洲为16.7/万，北美为31.9/万，拉丁美洲为10.2/万，非洲为1万，人均确诊7.4。

市场细分

β-内□胺有望在细菌感染治疗市场占据最大份额

按治疗剂，市场分为 β-内□胺类、奎诺酮类、大环内酯类、四环素类、磺胺类等。 β-内□胺预计将占据最大份额，因为它们是用于预防和治疗细菌感染的处方最多的抗生素。 β-内□胺通过抑制细胞壁合成起作用。 β-内□胺类抗生素靶向青霉素结合蛋白 (PBP)，该蛋白参与细菌细胞壁的交联。 β-内□胺类抗生素对广泛的临床适应症有效。青霉素类、头孢菌素类、碳青霉烯类和单环内□胺类是市场上使用最广泛的β-内□胺类抗生素。

β-内□胺类药物的研发活动正在加强。例如，2019年3月，Iterum Therapeutics宣布口服和静脉注射（IV）sulopenem製剂在社区获得性肺炎、急性细菌性前列腺炎、淋球菌性尿道炎和盆腔炎四个新适应症：获得合格传染病产品（ QIDP) 和美国食品和药物管理局 (FDA) 的快速通道指定。 Sulopenem 还被批准用于治疗非复杂性尿路感染 (uUTI)、复杂性尿路感染 (cUTI) 和復杂的腹腔内感染 (cIAI)，符合合格传染病产品 (QIDP) 和 First I 的跟踪指定。

通过分销渠道，预计零售药店的销售额在预测期内将快速增长

市场按分销渠道分为医院药房、零售药房、在线药房等。由于零售药店和药店提供治疗细菌感染的药物，预计零售药店的市场增长率最高。全球零售商店的数量正在增加。一项横断面调查发现，大约 93.5% 的抗生素，包括阿莫西林和復方磺胺甲噁唑，是由大多数註册药店开具的。

区域分析

北美在全球治疗细菌感染的药物市场中占有最大的市场份额。

由于细菌感染的流行率不断上升，北美地区将在 2021 年占据全球细菌感染治疗市场的最大市场份额。根据美国疾病控制与预防中心 (CDC) 的数据，到 2021 年，结核病将影响美国 7,860 人。 2019 年美国的沙门氏菌和莱姆病也分别占 58,371 和 34,945 例。抗生素耐药性感染很普遍。根据美国疾病控制和预防中心 (CDC) 的数据，2019 年每年有超过 280 万人遭受抗生素耐药性感染。每年有超过 35,000 人死于抗生素耐药性感染。

由于大量使用治疗剂来治疗细菌感染，美国占据了最高的市场份额。根据美国疾病控制和预防中心 (CDC) 的数据，医疗保健专业人员开出的抗生素数量为 2.702 亿，即每 1,000 人使用 836 种抗生素。此外，细菌感染治疗药物的批准和上市也在取得进展。例如，2020 年 6 月 4 日，美国食品和药物管理局批准了 Recarbrio。 Recarbrio 旨在治疗 18 岁及以上患者的医院和呼吸机相关细菌性肺炎。预计在预测期内，抗菌剂的容易获得将刺激市场增长。

预计亚太地区将在预测期内以最快的复合年增长率增长

由于人口老龄化导致细菌感染的增加，预计亚太地区将成为全球细菌感染治疗市场增长最快的地区。 .根据联合国的一份报告，印度有大约 8700 万 65 岁以上的人口。此外，增加对医疗设施和基础设施发展的投资预计将对市场产生积极影响。

用于开发治疗细菌感染的治疗药物的研究和开发活动也很活跃。有多个市场参与者正在开发治疗细菌感染的疗法。人们越来越意识到使用抗菌剂治疗细菌感染。预计在预测期内，人口收入和购买力的提高将增加对细菌感染药物的需求。

竞争格局。

细菌感染治疗市场是一个分散的市场，市场参与者众多。诺华公司、葛兰素史克公司、辉瑞公司、默克公司、赛诺菲公司、艾尔建公司、拜耳公司、阿斯利康公司、百时美施贵宝公司、武田製药有限公司、礼来公司、强生公司和梯瓦製药工业有限公司是具有较大市场份额的主要参与者。公司正在采取多种增长战略，例如产品批准、产品发布、收购、合併、合作伙伴关係和许可，以增加其市场占有率。例如：

併购与合作

2019 年 7 月，Nosopharm 与 Evotec SE 合作，将 NOSO-502（一种针对肠桿菌感染的新型抗生素）推进到医院获得性和呼吸机相关性肺炎 (HAP/VAP) 的临床阶段开发。已同意开发第二代Odilorhabdin用于治疗

产品发布和批准

2019 年 7 月，默克公司获得了美国食品药品监督管理局 (FDA) 的批准，用于注射 1.25 克 Recarbrio（亚胺培南、西司他丁、瑞巴坦），这是一种新的联合抗生素。 Recarbrio 用于治疗复杂的尿路感染 (cUTI)，包括由阴沟肠桿菌、大肠桿菌、产气克雷伯菌、肺炎克雷伯菌和铜绿假单胞菌等易感革兰氏阴性菌引起的肾盂肾炎，替代治疗选择有限。 18 岁以上的患者有或没有

2019 年 7 月，默克公司获得美国食品药品监督管理局 (FDA) 的批准，用于治疗 18 岁及以上患者的医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎 (HABP)，用于治疗 Zerbaxa（头孢唑烷和他唑巴坦） ）。/VABP）。

艾尔建批准了 Avycaz（通用名：头孢他啶、avibactam）的附加适应症，用于治疗由以下革兰氏阴性菌（包括肺炎克雷伯菌）引起的医院获得性肺炎和呼吸机相关性细菌性肺炎 (HABP/VABP)：我得到了，所以我得到了会让你知道的。适用于 18 岁及以上的患者，包括阴沟肠桿菌、大肠桿菌、粘质沙雷氏菌、奇异变形桿菌、铜绿假单胞菌和流感嗜血桿菌。

2019 年 8 月 19 日，美国食品和药物管理局批准 Zenreta 用于治疗成人社区获得性肺炎。这种新药为治疗社区获得性细菌性肺炎患者提供了更好的选择。

接管。

2020 年 2 月，Grifols 收购了抗生素开发商 Aradigum。

2021 年 10 月 11 日，山德士完成了对葛兰素史克头孢菌素业务的收购，确认了山德士对抗生素业务的承诺。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按疾病类型划分的市场细分
  • 按药物划分的市场细分
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 不断增长的老年人口
      • 细菌感染增加
    • 限制因素
      • 治疗药物的副作用
      • 基因突变
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疾病类型

  • 细菌性皮肤感染
  • 食物中毒感染
  • 性传播疾病
  • 其他

第8章药物

  • β-内□胺系统
  • 奎诺酮类
  • 大环内酯类
  • 四环素类
  • 磺胺类系统
  • 其他

第 9 章给药途径

  • 口语
  • 局部给药
  • 家长代理
  • 其他

第10章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 13 章公司简介

  • 诺华公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • GlaxoSmithkline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Allergan
  • Bayer AG
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Baxter
  • Eli Lilly and Company
  • Johnson and Johnson
  • Insmed, Inc.
  • Otsuka Pharmaceuticals Co., Ltd.
  • Roche Holding AG
  • Forest Laboratories, Inc.
  • Teva Pharmaceuticals Industries Ltd.（LIST NOT EXHAUSTIVE）

第14章 DataM

简介目录
Product Code: DMPH2790

Market Overview

Bacterial Infectious Diseases Therapeutics market was valued at USD 75.8 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Bacterial infectious diseases are infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including rod-shaped (bacilli), spherical (cocci), or helical (spirilla).

Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by various signs and symptoms including bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.

Market Dynamics

Growing Older Population is Driving the Growth of the Market

The demand for bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at a high risk of developing bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.

According to the United Nations (UN) report, the older population of age-group 65 years or above was 727 million worldwide in 2020. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has a higher older population in comparison to Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.

Increasing Antibacterial Resistance is Expected to Boost the Development of Therapeutics over the Forecast Period.

There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)'s new Global Antimicrobial Surveillance System (GLASS), antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 86% of new TB cases in 30 high TB burden countries in 2020.

Several factors such as misuse and overuse of antibacterial, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in healthcare facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is a rising spread of multi- and pan-resistant bacteria infections not being treatable by using the existing antibacterial worldwide. The increasing antibacterial resistance has resulted in the rising development of therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of several therapeutics being developed. Several companies are developing therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterial. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in the pipeline, only six were classified as innovative.

Rising Organizations & Institutes Initiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth

Several organizations & institutes have raised initiatives for overcoming antibacterial resistance. For instance, The India government has launched a "National Programme on AMR Containment during the 12th five-year plan, which is coordinated by NCDC. This phased manner included 35 state medical college labs and 26 states/UT. World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.

The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.

COVID-19 Impact Analysis

The bacterial infectious diseases therapeutics has witnessed drastic growth with the increasing number of people suffering from the COVID-19 as the antibacterial are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumonia, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.

According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology & infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections. Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Market Segment Analysis

Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market

By therapeutics, the market is classified as beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. The Beta-lactam segment is anticipated to hold the largest share as it is the most prescribed antibacterial for the prevention & treatment of bacterial infection. The beta-lactam acts by inhibiting cell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. B-Lactam antibiotics are effective against a broad range of clinical indications. Penicillin's, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterial with the highest market penetration.

There is increasing research and development activities for beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).

By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies are segmented to have the highest market growth due to the high availability of therapeutics for the treatment of bacterial infectious diseases in the retail pharmacies & drug stores. There is an increase in the number of retail stores across the globe. According to the cross-sectional survey, approximately 93.5% of antibiotics including amoxicillin and trimethoprim-sulfamethoxazole were prescribed by the majority of the registered drug shops.

Geographical Analysis

North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market

North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2021 owing to the increasing prevalence of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 7,860 in the United States in 2021. The total number of incidence cases of salmonella and Lyme disease was 58,371 and 34,945 respectively in the United States in 2019. There is a growing prevalence of antibacterial resistant infections. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by antibiotic-resistant infections 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.

The United States accounts for the highest market share due to the higher usage of therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of therapeutics for the treatment of bacterial infectious diseases. For instance, on 4th June 2020, the United States Food and Drug Administration approved Recarbrio. The Recarbrio is to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older. The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of the population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.

There is increasing research and development activities for the development of therapeutics for the treatment of bacterial infectious diseases. There is a presence of several market players developing therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.

Competitive Landscape:

The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of a large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and develop a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)

Product Launch & Approvals:

In July 2019, Merck & Co. had received approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumonia, and Pseudomonas aeruginosa.

In July 2019, Merck & Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenza in patients 18 years of age or older.

On 19th August 2019, The United States Food and Drug Administration approved Xenleta to treat adults with community-acquired bacterial pneumonia. This new drug provides a better option for treating patients with community-acquired bacterial pneumonia.

Acquisition:

In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.

On 11th October 2021, Sandoz completed the acquisition of GSK's cephalosporin business, confirming Sandoz's commitment to the antibiotics business.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Therapeutics
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Older Population
      • 4.1.1.2. Increasing Prevalence of Bacterial Infectious Diseases
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Therapeutics
      • 4.1.2.2. Genetic Mutations
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Bacterial Skin Infections*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Foodborne Bacterial Infections
    • 7.3.3. Sexually Transmitted Bacterial Infections
    • 7.3.4. Others

8. By Therapeutics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 8.3. Market Attractiveness Index, By Therapeutics Segment
    • 8.3.1. Beta-Lactam*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Quinolones
    • 8.3.3. Macrolides
    • 8.3.4. Tetracyclines
    • 8.3.5. Sulfonamide
    • 8.3.6. Others

9. By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Topical
    • 9.3.3. Parenteral
    • 9.3.4. Others

10. By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Hospitals Pharmacies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
    • 10.3.4. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. GlaxoSmithkline plc
  • 13.3. Pfizer Inc.
  • 13.4. Merck & Co., Inc.
  • 13.5. Sanofi
  • 13.6. Allergan
  • 13.7. Bayer AG
  • 13.8. AstraZeneca Plc
  • 13.9. Bristol-Myers Squibb Company
  • 13.10. Takeda Pharmaceutical Company Limited
  • 13.11. Baxter
  • 13.12. Eli Lilly and Company
  • 13.13. Johnson and Johnson
  • 13.14. Insmed, Inc.
  • 13.15. Otsuka Pharmaceuticals Co., Ltd.
  • 13.16. Roche Holding AG
  • 13.17. Forest Laboratories, Inc.
  • 13.18. Teva Pharmaceuticals Industries Ltd. (LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us